TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04880122

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dried blood spot and venous blood collection
Description: A paired venous blood and capillary blood sample (dried blood spot) were collected in every participant for validation purpose. Venous blood samples were analyzed using a chemiluminescent microparticle immunoassay ( the Architect i2000sr Plus system, Abbott), as a reference. Dried blood spots (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany) or (Whatman™, GE Healthcare Sciences, Cardiff, UK) were analyzed by means of a SARS-CoV-2 IgG ELISA (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany).
Study: NCT00003141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT02463461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiSleep Activity Monitor
Description: Subjects in this group will wear a ActiSleep Activity Monitor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jawbone Activity Monitor
Description: Subjects in this group will wear a Jawbone Activity Monitor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actiwatch 2 Activity Monitor
Description: Subjects in this group will wear a Actiwatch 2 Activity Monitor.
Study: NCT02463461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit Activity Monitor
Description: Subjects in this group will wear a FitBit Activity Monitor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraph by Ambulatory Monitoring Activity Monitor
Description: Subjects in this group will wear a Actigraph by Ambulatory Monitoring Activity Monitor.
Study: NCT00588367

Intervention type: DEVICE
Intervention: Mayo Interactive Breath Hold Monitor
Description: Biofeedback device

Intervention type: DEVICE
Intervention: Mayo Interactive Breath Hold Monitor
Description: Biofeedback device

Intervention type: DEVICE
Intervention: Mayo Interactive Breath Hold Monitor
Description: Biofeedback device
Study: NCT02690701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Description: Secukinumab 300 mg was provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab consisted of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occurred on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided in 1 mL prefilled syringe. Each placebo dose consisted of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3, 4), then after four weeks at Week 8. At Week 12, patients were switched to receive 300 mg secukinumab once weekly for five weeks (Weeks 12, 13, 14, 15, 16) followed by monthly dosing through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occured on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home.
Study: NCT00424398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepreve
Description: sterile ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile ophthalmic solution
Study: NCT00424398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine Besilate
Description: sterile ophthalmic solution
Study: NCT03097380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2115
Description: AZD2115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPIRIVA
Description: Tiotropium

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]AZ13754366
Description: Radioligand

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: [11C]AZ13754366
Description: Radioligand

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]AZ13754366
Description: Radioligand
Study: NCT01339442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study: NCT01190930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO
Study: NCT01339442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study: NCT01284803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an educational intervention
Description: To elaborate an educational program for the management of depression in primary care
Study: NCT04268719

Intervention type: DIAGNOSTIC_TEST
Intervention: wireless pH capsule recording
Description: wireless pH capsule recording for up to 96 hours

Intervention type: DIAGNOSTIC_TEST
Intervention: wireless pH capsule recording
Description: wireless pH capsule recording for up to 96 hours
Study: NCT04178655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: 1 GRAM TRANEXAMIC ACID INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: 10 MILILITERS 0.9% NORMAL SALINE INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
Study: NCT02345798

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Follow-Up Care
Description: Undergo usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caregiver-Related Intervention or Procedure
Description: Undergo video-assisted intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Undergo video-assisted intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Undergo quality of life assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Undergo quality of life assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Undergo questionnaire administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Undergo questionnaire administration
Study: NCT00714779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: 20-40 mg / day orally

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short-term psychodynamic psychotherapy
Description: 1 session / week for 16 weeks
Study: NCT02755402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xpert HCV Viral load
Description: HCV viral load testing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transient elastography
Description: Evaluation of liver fibrosis
Study: NCT01349309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swallowing Exercise Group
Description: Swallowing Exercises~Perform each exercise 10 times. Do these 3 times a day. Vary the order of the exercises.~Effortful Swallow: As you swallow squeeze hard with all your muscles. (Can do with water or without)~Super Supraglottic Swallow:~Inhale and hold your breath very tightly, bearing down. Keep holding your breath and bearing down as you swallow. Cough when you are finished. (Can do with water or without)~Tongue Hold Maneuver:~Gently hold your tongue in between your front teeth and swallow your saliva.~Tongue Retraction:~Pull the back of your tongue to the back of your mouth and hold.~Mendelsohn Maneuver:~Swallow your saliva and pay attention to your neck as you swallow. Try to feel that something (your Adam's apple of voice box) lifts and lowers as you swallow. Now, when you swallow and you feel something lift as you swallow don't let it drop. Hold it with your muscles for several seconds.
Study: NCT04410874

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imvamune
Description: Imvamune vaccine to be administered (via injection) intratumorally at one of three doses (1x10\^7, 1x10\^8, or 4x10\^8 PFU) twice, 4 days apart (first injection on Day 0 of the study and second injection on Day 4)
Study: NCT01082484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil
Description: Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost
Description: Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
Study: NCT01190930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO
Study: NCT03476642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: injection of 20mL epinephrine in combination with ropivacaine at the left or right T5 transverse process
Study: NCT01082484

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
Study: NCT00898092

Intervention type: GENETIC
Intervention: microarray analysis

Intervention type: GENETIC
Intervention: molecular genetic technique

Intervention type: GENETIC
Intervention: mutation analysis

Intervention type: GENETIC
Intervention: polymerase chain reaction

Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction

Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Study: NCT00539019

Intervention type: OTHER
Intervention: calories measured 5x following wound healing
Description: measure REE at various time points postburn
Study: NCT01272583

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: 100 mg once daily for six weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: 100 mg once daily for six weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: placebo, once daily for six weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: placebo, once daily for six weeks
Study: NCT03700957

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid
Description: 100 milligrams of Docosahexaenoic Acid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04324853

Intervention type: DIAGNOSTIC_TEST
Intervention: Microscopy ( Urine filtration), UCAA test, qPCR,
Description: Schistosomiasis is an acute and chronic parasitic disease caused by blood flukes (trematode worms) of the genus Schistosoma.Schistosomiasis is prevalent in tropical and subtropical areas, especially in poor communities without access to safe drinking water and adequate sanitation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Microscopy (Kato Katz, Coproculture, Harada Mori, MIF), qPCR,
Description: Soil-transmitted helminth infections are among the most common infections worldwide and affect the poorest and most deprived communities. They are transmitted by eggs present in human faeces which in turn contaminate soil in areas where sanitation is poor.

Intervention type: DIAGNOSTIC_TEST
Intervention: Microscopy (Kato Katz, Coproculture, Harada Mori, MIF), qPCR,
Description: Soil-transmitted helminth infections are among the most common infections worldwide and affect the poorest and most deprived communities. They are transmitted by eggs present in human faeces which in turn contaminate soil in areas where sanitation is poor.
Study: NCT02154399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF5
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery/thoracotomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue Oxygen Measurement
Description: Undergo tumor hypoxia measurement
Study: NCT00749203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: single dose 0.045 mg/kg IV infused over 40 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
Study: NCT01907165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Copper gluconate
Study: NCT01572155

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus stimulation 1
Description: 2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus stimulation 2
Description: 2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
Study: NCT02150031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% Chlorhexidine
Description: mouthwash with 10 ml for 1 minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% Chlorhexidine
Description: mouthwash with 10 ml for 1 minute
Study: NCT01190930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT00764517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01190930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT01469767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinonide cream
Description: Fluocinonide cream 0.1% applied twice daily for 5 days.
Study: NCT01314417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 400 μg/100 μL monthly injections for the first 3 months, then as needed per the treatment criteria
Study: NCT00287092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DT5aP-IPV-Hib 5-component Pertussis vaccine
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix® -IPV+Hib
Description: 0.5 mL, IM
Study: NCT01133353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrabenazine MR
Description: Modified-Release (MR) tablets containing 15 mg or 30 mg tetrabenazine, dose-escalating up to a maximum of 150 mg depending on weight, once per day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 to 5 tablets once per day depending on weight for 12 weeks
Study: NCT03919630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrust Mobilization
Description: Once therapist has assessed subject and has found the patients most comparable sign they will be performing a high velocity thrust at the end of the patients available range, as described by Maitland's Approach. The thrust will be performed only once. The therapist will perform either a localized cervical rotation thrust which primary movement is rotation or a longitudinal cephalad C1 and C2 thrust, both targeting the upper cervical spine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Thrust Mobilizations
Description: Therapists will perform unilateral posterior to anterior mobilization (UPA) or central posterior to anterior (CPA) mobilizations grades I-IV as described above by Maitland concepts at levels C0-C3 which reproduce the patient's most comparable sign. Therapists will be instructed to perform 3x 30 second bouts of mobilizations at that level.
Study: NCT02939092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomegranates peel extract
Description: Pomegranate is antimicrobial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Chlorhexidine mouthwash is antiplaque agent
Study: NCT04446559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sitting in chair position
Description: For patients randomized in the chair group, we will perform the transfer to the chair immediately after the morning arterial blood gas. The chair position will be maintained for 3 hours, if the patient shows no clinical signs of discomfort or intolerance.
Study: NCT03770598

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Distressed in study Arm Distressed
Description: Social worker evaluation and possible referral to Psychiatry/Psychology for evaluation and further treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-Education
Description: Mindfulness based stress reduction class, yoga and education material

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Team Based Care
Description: Psychiatrist, Oncologist, clinical social worker, study coordinator

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Non-Distressed
Description: No psycho-education about wellness promotion or health. These patients will be monitored only.
Study: NCT02428127

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage powder
Description: Carbohydrate beverage powder fortified with multiple micronutrients. 20g of study product will be administered orally twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calorie matched beverage powder
Description: Calorie matched beverage powder with 80% protein.20g of study product will be administered orally twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: lukewarm water
Study: NCT05008978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test 1
Description: 25g of available carbohydrates from White bread with 25g of available carbohydrates from Banana consumed simultaneously at time 0 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test 2
Description: 25g of available carbohydrates from Banana consumed at time -15 min and 25g of available carbohydrates from white bread consumed at time 0 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test 3
Description: 25g of available carbohydrates from White bread consumed at time 0 min and 25g of available carbohydrates from Banana consumed at time 15 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test 4
Description: 25g of available carbohydrates from White bread with 25g of available carbohydrates from Papaya consumed simultaneously at time 0 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test 5
Description: 25g of available carbohydrates from White bread with 25g of available carbohydrates from Apple consumed simultaneously at time 0 min
Study: NCT00764517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT03431272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Eye drop
Study: NCT01002820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganaxolone
Description: liquid suspension, 50 mg/mL, up to 500 mg/day TID or 1500 mg/day, up to 1 year